The Global X Defense Tech ETF (NYSEARCA:SHLD) and the SPDR S&P Aerospace & Defense ETF (NYSEARCA:XAR) look like two ways to buy the same rearmament story, but they take structurally different bets. One is a global, market-cap bet on next-generation defense platforms and European primes. The other is an equal-weight bet on the U.S. aerospace and defense supply chain, Boeing and all. That structural gap explains why XAR has returned 39.14% over the past year while SHLD has returned 10.46%, a reversal of the trade that worked in 2024.
What each fund is actually betting on
XAR tracks the S&P Aerospace & Defense Select Industry Index using modified equal-weighting. That construction is the whole story: small and mid-cap suppliers get weights close to Lockheed and RTX. XAR is really a bet that the entire U.S. defense industrial base, from engine makers to munitions specialists to Boeing’s commercial recovery, gets repriced together. It needs a broad cyclical lift, not a specific theme.
SHLD is the opposite. It is concentrated, global, and thematic. Lockheed Martin sits at 9.461% of assets, RTX at 7.922%, and General Dynamics at 7.152%, with the top three positions alone representing 24.535% of the fund. Then the fund pivots overseas: Rheinmetall (6.777%), BAE Systems (4.604%), Thales (4.167%), Leonardo (4.153%), and Saab (4.060%) anchor a heavy European rearmament tilt, joined by Hanwha Aerospace at 4.238% and Elbit Systems at 3.169%. The defense-tech signature comes from Palantir at 5.601%, plus Kratos, AeroVironment, and BlackSky. SHLD needs the NATO spending surge and the software-defined warfare thesis to keep paying.
Where the difference showed up
In 2024 and early 2025, SHLD was the trade. European defense stocks repriced violently on NATO commitments and Germany’s fiscal shift, and SHLD’s Rheinmetall, BAE, and Leonardo positions carried the fund. Since inception in September 2023, SHLD is up 166.56%.
The trade rotated in 2026. XAR is up 20.18% year to date while SHLD sits at 0.4%. European primes cooled after their run, Palantir traded sideways at high multiples, and U.S. mid-cap suppliers, the ones XAR overweights, caught a bid as the FY 2027 defense request pushed $52.9 billion into critical munitions and $59.7 billion into space, more than double the FY 2026 space level. That budget mix flows straight into the smaller names XAR equal-weights, not the primes SHLD concentrates.
The practical comparison
| Factor | SHLD | XAR |
|---|---|---|
| Strategy | Global defense-tech, market-cap | U.S. A&D, modified equal-weight |
| Top 3 concentration | 24.535% | Diffuse (equal-weight) |
| International exposure | Heavy (Europe, Korea, Israel) | None |
| Net assets | $7.53 billion | Not disclosed here |
| Expense ratio | 0.49% | Not disclosed here |
| YTD 2026 return | 0.4% | 20.18% |
The verdict
These funds serve different purposes. SHLD is the right vehicle for investors who want the modernization thesis in its purest form: European rearmament, AI-enabled warfare, autonomous systems, and space. It will lead when geopolitical shocks and defense-tech capex expand together, and it will lag when the trade rotates into cyclical U.S. suppliers, as it has this year.
XAR fits investors who want cyclical exposure to the whole U.S. aerospace and defense complex, including a Boeing recovery and the smaller munitions and space names now benefiting from the FY 2027 budget mix. Its 451.76% ten-year return reflects that broader base. Owning both makes sense only if an investor genuinely wants two distinct exposures. What would flip the call back to SHLD: a fresh NATO spending shock or an escalation that reprices European primes the way 2024 did.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks